AZN - AstraZeneca • Financials

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2020	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2021	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2022	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2023	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12/2024	54,073	16,691	-	13%	4.5	40,786	17%	23,189	1.4	11,861	-4,586	-3,996	7,275	-81	-4,629	66%	2.3%
12/2024	54,073	16,691	-	13%	4.5	40,786	17%	23,189	1.4	11,861	-4,586	-3,996	7,275	-81	-4,629	66%	2.3%
12/2025	58,739	19,476	-	17%	6.6	48,667	21%	22,078	1.1	14,575	-5,905	-7,544	8,670	-521	-4,971	49%	1.8%

To see all financials—including updated, you must be Premium.